If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Shobha Swaminathan is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 5 Similar Profiles
HIV Medicine & Life Sciences
Acquired Immunodeficiency Syndrome Medicine & Life Sciences
Tuberculosis Medicine & Life Sciences
efavirenz Medicine & Life Sciences
Glutathione Medicine & Life Sciences
Clinical Trials Medicine & Life Sciences
Papillomaviridae Medicine & Life Sciences
Tenofovir Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2006 2019

  • 121 Citations
  • 6 h-Index
  • 14 Article
  • 1 Chapter
  • 1 Letter
1 Citation (Scopus)

Antiretroviral therapy and vaginally administered contraceptive hormones: a three-arm, pharmacokinetic study

AIDS Clinical Trials Group A5316 Study Team, Sep 2019, In : The Lancet HIV. 6, 9, p. e601-e612

Rutgers, The State University

Research output: Contribution to journalArticle

efavirenz
Contraceptive Agents
Ethinyl Estradiol
Pharmacokinetics
Hormones

Low Rate of Sex-specific Analyses in Presentations at the Conference on Retroviruses and Opportunistic Infections (CROI) Meeting, 2018: Room to Improve

for the Women's Health Inter-Network Scientific Committee (WHISC), Aug 15 2019, In : Journal of Acquired Immune Deficiency Syndromes. 81, 5, p. E158-E160

Rutgers, The State University

Research output: Contribution to journalLetter

Open Access
Acquired Immunodeficiency Syndrome
Research Personnel
Clinical Trials
HIV
Research

Perspectives of US women participating in a candidate PrEP study: adherence, acceptability and future use intentions

HPTN 069/A5305 Study Team and HPTN Women at Risk Committee, Mar 2019, In : Journal of the International AIDS Society. 22, 3, e25247.

Rutgers, The State University

Research output: Contribution to journalArticle

Open Access
Interviews
HIV
Pre-Exposure Prophylaxis
Ownership
Risk-Taking